ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年12月05日 09時00分
Source:
Eisai
エーザイ、第42回サンアントニオ乳がんシンポジウムにおいてエリブリン(ハラヴェン(R))に関する演題を発表
東京, 2019年12月05日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、2019年12月10日から14日まで米国テキサス州サンアントニオで開催される「第42回サンアントニオ乳がんシンポジウム(San Antonio Breast Cancer Symposium:SABCS2019)」において、当社が創製したエリブリンメシル酸塩(ハリコンドリン系微小管ダイナミクス阻害剤、製品名:「ハラヴェン(R)」、以下 エリブリン)に関する最新情報を発表することをお知らせします。
本学会では、進行性または転移性乳がん患者様を対象としたエリブリンの2つの臨床第III相試験の追加事後解析から全生存期間の予測因子としてエリブリン投与前時点におけるリンパ球数を評価した研究結果など、ポスター5演題が発表されます。
当社は、がん領域を重点領域の一つと位置づけており、がんの「治癒」に向けた革新的な新薬創出をめざしています。最先端のがん研究から革新的な創薬を行い、がん患者様とそのご家族、さらには医療従事者の多様なニーズの充足とベネフィット向上に、より一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201988.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Feb 24, 2026 20:07 JST
MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST
Fujitsu expands Uvance for Finance offerings to accelerate DX across financial sector
Feb 24, 2026 11:23 JST
MHI Thermal Systems Establishes Local Subsidiary in India and Starts Operations
Feb 24, 2026 11:02 JST
Full Convertible Bond Conversion Removes Overhang and Signals Valuation Reassessment for Shoucheng Holdings
Feb 20, 2026 20:32 JST
Investee Companies Take the National Stage: Shoucheng Holdings' 'Capital+Scenario+Industry Chain' Strategy Validated, Entering the Value Realization Phase
Feb 20, 2026 20:06 JST
Hitachi Rail Invests C$30 Million in New Canadian Headquarters
Feb 20, 2026 12:20 JST
Toyota Launches New RAV4 (PHEV) in Japan
Feb 19, 2026 19:25 JST
Osaka Hospital launches project to safely utilize generative AI for healthcare workforce improvements
Feb 19, 2026 12:12 JST
MHI Machinery Systems Participates in Ramp Merging Support Demonstration Experiment for Autonomous Vehicles on the Tokyo Metropolitan Expressway
Feb 18, 2026 15:37 JST
IDC MarketScape names Hitachi Energy a Leader in Asset Performance Management for Worldwide Utilities
Feb 18, 2026 10:51 JST
Fujitsu named to FORTUNE Magazine's list of 'World's Most Admired Companie's for eighth year running
Feb 18, 2026 10:41 JST
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
Feb 17, 2026 22:00 JST
Fujitsu automates entire software development lifecycle with new AI-Driven Software Development Platform
Feb 17, 2026 12:21 JST
Snow master Evans leads 1-2-3-4 finish for TGR-WRT
Feb 16, 2026 15:24 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
Feb 16, 2026 14:03 JST
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
More Latest Release >>
Related Release
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2/6/2026 11:31:00 AM JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
More Press release >>